

Breast Surgery Fellowship Program

Surgical Leadership and Research




Memorial Sloan Kettering
Cancer Center

Training the Future Leaders of Cancer Care



CONTENTS

Welcome	2
History	3
Faculty	5
Education	45
Memorial Sloan Kettering Cancer Center.....	46
Fellowship Publications 2020-2025.....	49
Graduates of the Breast Service Fellowship Program	51



WELCOME

On behalf of the Breast Surgery Service, we are enthusiastic about your interest in our breast surgery fellowship program, which provides an outstanding surgical experience combined with an emphasis on multidisciplinary care and evidence-based management. After completion of our program, our trainees are well equipped to meet the challenges of breast cancer care in the 21st Century.

Monica Morrow

Chief, Breast Service, Department of Surgery

Anne Burnett Windfohr Chair of Clinical Oncology



HISTORY

The Josie Robertson Surgery Center



Evelyn H. Lauder Breast and Imaging Center (BAIC)

Memorial Sloan Kettering Cancer Center, the first cancer hospital in the United States, was founded in 1884 as New York Cancer Hospital on Manhattan's Upper West Side. In 1936, the hospital began a move to its present location on York Avenue, on land donated by John D. Rockefeller, Jr., and the new Memorial Hospital for the Treatment of Cancer and Allied Diseases opened in 1939. The building, which was renovated between 1970 and 1973, stands on this site today.

In the 1940s two former General Motors executives, Alfred P. Sloan and Charles F. Kettering, collaborated to establish the Sloan Kettering Institute (SKI), which has since become one of the nation's leading biomedical research institutions. Built adjacent to Memorial Hospital, SKI was formally dedicated in 1948.

In 1960, a new corporate entity—Memorial Sloan Kettering Cancer Center—was formed to coordinate and guide the overall policy for Memorial Hospital and the Sloan Kettering Institute. In 1980 these entities were unified into a single institution.

At present, MSK houses **514 inpatient beds**, and unites a team of **21,077 employees**, and **1,824 residents and fellows**. In 2023, MSK recorded 25,591 inpatient stays and provided over one million outpatient visits. According to US News & World Report, Memorial Sloan Kettering Cancer Center has ranked as one of the top two hospitals for cancer care in the United States for more than 30 years. Memorial Sloan Kettering Cancer Center is one of 73 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science floors side by side with clinical studies and treatment.

In 2015, a generous commitment from The Robertson Foundation made possible the creation of the MSK Josie Robertson Surgery Center, a new 16-story, 179,000-square-foot building located on Manhattan's Upper East Side. Over 20,000 operations are performed each year at Josie Roberston Surgery Center, including **4,500 breast operations**. Designed from the ground up with the surgical care needs and experience of patients and families foremost in mind, the Josie Robertson Surgery Center is a first-of-its-kind freestanding surgical facility where our surgeons can perform outpatient procedures in a state-of-the-art setting.

The MSK Ralph Lauren Center offers cancer prevention, diagnosis, treatment, and support services. Since its founding in 2003, the MSK Ralph Lauren Center has served New York City's Harlem community—a community with one of the highest cancer mortality rates in the nation—and surrounding neighborhoods by providing high-quality care in a warm, welcoming, and culturally sensitive environment. In keeping with its mission to diminish disparities and address historically underserved communities by increasing access to world-class cancer treatment, the MSK Ralph Lauren Center has cared for thousands of people, making it a beacon for compassionate cancer care for residents of Harlem and beyond.

The 6 MSK Basking Ridge, NJ, Bergen, NJ, Monmouth NJ, Nassau, NY, Commack, NY, and Westchester, NY satellite locations expand MSK's cancer treatment mission, and accessibility to its world-class cancer care—including chemotherapy, radiation, and immunotherapy—and its outpatient mastectomy program, to the greater New York, New Jersey, Connecticut area.

TIMELINE

1920-1933



Dr. Burton James Lee

The Breast Service at Memorial Sloan Kettering Cancer Center was established in 1920 with the founding of the Memorial Hospital Breast Clinic by its first chief, Dr. Burton James Lee. One of Memorial's charter members, Dr. Lee led the Breast Service to international renown as a model in the field of breast cancer treatment.

1933-1952



Dr. Frank Adair

In 1933 Dr. Lee was succeeded by Dr. Frank Adair, a pioneer in the combined use of radiation therapy, hormone therapy, and surgery in the treatment of breast cancer. Dr. Adair was a founding member of the clinical section of the Sloan Kettering Institute for Cancer Research.

1952-1960



Dr. Norman Treves

After Dr. Adair's retirement in 1952, Dr. Norman Treves was appointed chief of the Breast Service. An authority on breast tumors and lymphedema research, he co-discovered a rare complication of chronic lymphedema resulting from mastectomy and/or radiation therapy for breast cancer, which would be named Stewart-Treves syndrome.

1960-1969



Dr. Joseph Farrow

Dr. Treves was succeeded by Dr. Joseph Farrow as chief of the Breast Service in 1960. Dr. Farrow was one of the first breast cancer researchers to emphasize what is now called in situ carcinoma of the breast, a field which continues to occupy a prominent place in the research and treatment of breast cancer five decades later.

1979-1993



Dr. David Kinne

Dr. David Kinne, a pioneer in the field of breast-conservation therapy and a widely respected authority on breast cancer in the elderly, was appointed chief of the Breast Service in 1979.

1993-2006



Dr. Patrick Borgen

Dr. Kinne was succeeded in 1993 by Dr. Patrick Borgen. Under Dr. Borgen's stewardship, the Breast Service inaugurated the Breast Service Fellowship Program, one of the first of its kind in the United States, and one of the first such programs to receive Society of Surgical Oncology accreditation.

2008-Present



Dr. Monica Morrow

Dr. Monica Morrow was appointed chief of the Breast Service in 2008. Dr. Morrow served as president of the Society of Surgical Oncology in 2012-2013. Her research focuses on the application of advances from clinical trials to daily surgical practice.

FACULTY



Lisa R. Allen, MD, FACS

Associate Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center

Education: MD, State University of New York Upstate Medical University

Residency: Drexel University College of Medicine

Fellowship: University of Texas MD Anderson Cancer Center



Recent Highlights

Leadership

Member, Ethics Committee, American Society of Breast Surgeons

Site Surveyor, American College of Surgeons Commission on Cancer

Lisa R. Allen, MD, FACS, is an Associate Attending on the Breast Service, and sees patients at MSK Monmouth and MSK Basking Ridge in New Jersey. She operates at the MSK Josie Robertson Surgery Center in Manhattan and MSK Monmouth. Dr. Allen treats both men and women for all types of breast cancer, routinely using minimally invasive surgical techniques that involve making smaller incisions, and using the hidden scar approach to achieve excellent cosmetic results. Dr. Allen also performs surgery for high-risk lesions that carry a potential risk for breast cancer.

She has always been interested in the ethics of medicine, has served on hospital ethics committees throughout residency and her clinical practice, and currently sits on the ethics committee of the American Society of Breast Surgeons. She has clinical research interest in social determinants of health and has worked with a diverse population of patients over the last 13 years. She is interested in examining how artificial intelligence can play a role in breast cancer diagnosis, treatment, and supportive services. She currently serves as a site surveyor for the American College of Surgeons Commission on Cancer (and previously, for the National Accreditation Program for Breast Centers).



Andrea V. Barrio, MD, FACS

Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Surgery, Weill Cornell Medical College

Education: MD, University of California at Los Angeles School of Medicine

Residency: New York Presbyterian Hospital/Weill Cornell Medical Center

Fellowship: Memorial Sloan Kettering Cancer Center



Andrea V. Barrio, MD, FACS, is an Attending on the Breast Service. She sees patients at the MSK Westchester site in West Harrison, NY. Over the past several years, Dr. Barrio has also been involved in clinical research focused on the surgical management of the axilla after neoadjuvant chemotherapy and methods to avoid axillary lymph node dissection in this patient population. Her primary research interest has been the study of lymphedema in early-stage breast cancer patients. Her research has focused on methods to detect early signs of the condition and to study how early detection impacts long-term quality of life. Dr. Barrio is currently the principal investigator of a prospective lymphedema surveillance program for the assessment and treatment of breast cancer-related lymphedema after axillary lymph node dissection. This study began accruing patients in September 2016 at the Evelyn H. Lauder Breast Center. Her hope is that by better understanding the consequences and side effects of breast cancer treatment, we can work to enhance every patient's quality of life.

Recent Highlights

Grants

NIH R01 CA278599-01: Mechanisms of racial disparity in breast cancer-related lymphedema.

NIH/NCI Omnibus R03: Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer: A Prospective Study.

Leadership

Society of Surgical Oncology, Women in Cancer Surgery

Board Examiner, Complex General Surgical Oncology

Publications

Roberts A, Campbell AC, Pollack BL, Montagna G, Sevilimedu V, Axelrod B, Gomez EA, Giri D, Morrow M, Mehrara BJ, Barrio AV. Racial and Ethnic Differences in Breast Inflammation and Its Association with Lymphedema Risk After Axillary Lymph Node Dissection. *Ann Surg Oncol* 2025 (epub ahead of print).



Deborah M. Capko, MD, FACS

Associate Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Surgery, Weill Cornell Medical College

Education: MD, University of Medicine and Dentistry of New Jersey

Residency: University of Medicine and Dentistry of New Jersey

Fellowship: European Institute of Oncology



Recent Highlights

Service

NJ Monthly Magazine Top Doc Award

Publications

Jones VM, Nelson JA, Sevilimedu V, Le T, Allen RJ, Jr., Mehrara BJ, Barrio AV, Capko DM, Heerdt AS, Tadros AB, Gemignani ML, Morrow M, Sacchini V, Moo TA. Impact of Mastectomy Flap Necrosis on Patient-Reported Quality-of-Life Measures After Nipple-Sparing Mastectomy: A Preliminary Analysis. Ann Surg Oncol 2024;31(10):6795-803.

Deborah M. Capko, MD, FACS, is a surgical oncologist and a member of the Breast Surgical Service at Memorial Sloan Kettering Cancer Center (MSK) in New York and New Jersey.

Dr. Capko sees new patients at MSK Basking Ridge and MSK Middletown in New Jersey, and she performs most of her surgical procedures at MSK Middletown, and at MSK in New York City as needed. Dr. Capko works in partnership with the Nurse Practitioners at both Basking Ridge and Monmouth overseeing the RISE (Risk assessment, Imaging, Surveillance, and Education) high-risk breast cancer program.

Dr. Capko has provided breast cancer care to women in New Jersey for 23 years, and her major focus is on clinical patient care. Her clinical interests are in the de-escalation of axillary surgery for breast cancer management and in nipple-sparing mastectomy. She enrolls patients in the research trials available at MSK Basking Ridge and expedites entry into the clinical trials system at MSK's New York City location, when appropriate.




Daniel X. Choi, MD, FACS

Associate Attending, Breast Surgical Service
Director, Medical Student Program
Memorial Sloan Kettering Cancer Center
Associate Professor, Weill Cornell Medical College

Education: MD, The University of Chicago

Residency: The University of Rochester

Fellowship: Memorial Sloan Kettering Cancer Center



Recent Highlights

Leadership

Director, Medical Student Program

Dr. Daniel Choi sees patient at the MSK Commack location on Long Island. He also oversees our medical student education program. After completing a fellowship in breast surgical oncology at Memorial Sloan Kettering Cancer Center, he joined the United States Air Force. For a decade, he was assigned to the David Grant USAF Medical Center, Travis Air Force Base in California—the U.S. Air Force’s largest hospital—where he eventually achieved the rank of Lieutenant Colonel and was appointed Deputy Squadron Commander and Chief of Surgery. There, he helped build a breast program that provided care to patients from across the globe. On his 2 overseas deployments, he also founded a breast cancer treatment program in Afghanistan with the mission of delivering advanced care to an underserved population of women with cancer.



Stephanie Downs-Canner, MD, FACS

Assistant Attending, Breast Surgical Service
Director, Breast Fellowship Program
Director, Resident Program
Memorial Sloan Kettering Cancer Center
Assistant Professor of Surgery, Weill Cornell Medical College

Education: MD, University of Pittsburgh School of Medicine

Residency: University of Pittsburgh School of Medicine

Postdoctoral Research Fellowship: University of Pittsburgh Hillman Cancer Center

Fellowship: Memorial Sloan Kettering Cancer Center



Stephanie Downs-Canner, MD, FACS, is a breast surgical oncologist specializing in the treatment of patients with breast cancer, and a translational investigator embedded with the Sloan Kettering Institute. She sees patients at Memorial Sloan Kettering's Westchester, NY facility. Dr. Downs-Canner's NIH-funded research focuses on the role that immune cells play in the enhancement of the body's own immune response, and on the B-cell's importance to the efficacy of checkpoint blockade immunotherapy. She works with a team of researchers at Sloan Kettering Institute on a range of basic and translational science. She has also created a prospective database of patients with triple negative breast cancer treated with neoadjuvant immunotherapy, which has resulted in robust cross-disciplinary collaborations for the Breast Service.

In virtually every year of her career since graduating from medical school, Dr. Downs-Canner garnered recognition for excellence in mentoring and teaching. Prior to joining the faculty at MSK, her teaching and mentoring awards included Excellence in Resident Teaching, Excellence in Medical Student Teaching, Clinical Preceptor of the Year, the Craver Teaching Award, and Best New Faculty Member. She currently directs the Breast Surgery Fellowship Program at MSK.

Recent Highlights

Grants

NIH (NCI) 1 KO8 CA259533-01A1 The role of B-cells in the anti-tumor immune response in triple negative breast cancer

Specialized Program of Research Excellence (SPORE) in Breast Cancer Developmental Research Program (DRP) Awards: The impact of tumor microenvironment pH on the role of HVCN1 in B cell anti-tumor immunity

Leadership

Director, Breast Surgery Fellowship Program

Member, Program Directors Committee, Society of Surgical Oncology

Member, Constitution and Bylaws Committee, Society of Surgical Oncology

Publications Committee, American Society of Breast Surgeons

Immuno-Oncology Working Group, Translational Breast Cancer Research Consortium

Editorial Board, Surgical Oncology Insight

Publications

Perry LM, Sevilimedu V, Polidorio N, Abuhadra N, Morrow M, Plitas G, Downs-Canner S. Predictors of Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer. *Ann Surg Oncol*. 2025 Mar 2 (Epub ahead of print).

Kim Y, Manara F, Grassmann S, Belcheva KT, Reyes K, Kim H, Downs-Canner S, Yewdell WT, Sun JC, Chaudhuri J. IL-21 shapes the B cell response in a context-dependent manner. *Cell Rep*. 2025 Jan 28;44(1):115190.

Downs-Canner S, Mittendorf EA. Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study. *Ann Surg Oncol*. 2023 Jun;30(6):3166-3169.

Mai N, Myers S, Shen S, Downs-Canner S, Robson M, Norton L, Chen Y, Traina T, Abuhadra N. Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer. *NPJ Breast Cancer*. 2024 Jun 4;10(1):39.

Lue JK, Downs-Canner S, Chaudhuri J. The role of B cells in the development, progression, and treatment of lymphomas and solid tumors. *Adv Immunol*. 2022;154:71.

Myers SP, Sevilimedu V, Jones VM, Abuhadra N, Montagna G, Plitas G, Morrow M, Downs-Canner SM. Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer. *Ann Surg Oncol* 2024;31(8):5180-8.



Mahmoud B. El-Tamer, MD, FACS

Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Professor of Surgery, Weill Cornell Medical College

Education: MD, American University of Beirut

Residency: State University of New York Health Science Center at Brooklyn

Fellowship: Memorial Sloan Kettering Cancer Center



Mahmoud B. El-Tamer, MD, FACS, is a breast surgeon with over 30 years of experience caring for patients with breast cancer, and works collaboratively with other breast cancer specialists on Memorial Sloan Kettering Cancer Center's multidisciplinary breast cancer disease management team. After receiving surgical training in both oncologic and reconstructive procedures, Dr. El-Tamer developed an interest in joining these two disciplines with the goal of providing improved care to breast cancer patients, and he has developed a special expertise in this growing field of oncoplastic surgery. In 2013 he published a textbook entitled *Principles and Techniques in Oncoplastic Breast Surgery*, and in 2019 he published a second edition of this textbook in collaboration with other international breast surgeons entitled *Oncoplastic and Reconstructive Anatomy of the Breast*.

Dr. El-Tamer's research interests have covered different aspects of breast cancer and quality of care in surgery. He has served as principal or co-principal investigator on research grants from the Avon Breast Cancer Foundation, the United States Veterans' Administration, and the American College of Surgeons.

Dr. El-Tamer was the principal investigator for and is currently the co-holder of a U.S. patent for Detectably Labeled Porphyrin Compound for Identifying the Sentinel Lymph Node (US 6,458,336 B1; October 1, 2002). He has led an important investigation exploring the clinical significance of micrometastasis detected by immunohistopathology in patients with ductal carcinoma in situ (DCIS). The results of that research have helped clinicians seriously reconsider the role and the indication of sentinel-node dissection in patients with DCIS.

Dr. El-Tamer's research has also covered different clinical aspects of breast cancer in minority populations in the United States, quality of care in surgery, and breast cancer in men. He has written more than 125 book chapters, manuscripts, and editorials on these subjects.

Dr. El-Tamer was the one of the principal investigators who validated the applicability of the National Surgical Improvement Program (NSQIP) in the private sector, which has since been adopted by the American College of Surgeons as a quality-improvement guideline. He is one of the founding members of the National Accreditation Program for Breast Centers, and has served on its board of directors and as chair of its information technology and quality improvement committees.

Dr. El-Tamer is an active member of many leading professional societies, including the American College of Surgeons, the Society of Surgical Oncology, the American Society of Breast Surgeons, and the American Society of Breast Diseases.

Recent Highlights

Awards

Oncoplastic Breast Consortium 2020
Clinical trial leadership

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage I, HR+, HER2-, RS 18 breast cancer

The IDEA Study: Individualized Decisions for Endocrine therapy Alone

Publications

Williams AD, Pawloski KR, Wen HY, Sevilimedu V, Thompson D, Morrow M, El-Tamer M. Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age. *Breast Cancer Res Treat* 2022;196(3):565-70.

Montagna G, El-Tamer MB. Staging of the Axilla After Neoadjuvant Chemotherapy: Which Technique is Better? The Endless Debate. *Ann Surg Oncol* 2023;30(11):6290-6292.

Jagsi R, Griffith KA, Harris EE, Wright JL, Recht A, Taghian AG, Lee L, Moran MS, Small W, Jr., Johnstone C, Rahimi A, Freedman G, Muzaffar M, Haffty B, Horst K, Powell SN, Sharp J, Sabel M, Schott A, El-Tamer M. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA. *J Clin Oncol* 2024;42(4):390-8.

Palmquist E, Sevilimedu V, Garcia P, Le T, Zhang X, Pinker-Domenig K, Hanna MG, Nelson JA, Morrow M, El-Tamer M. Patient-Reported Outcomes in Patients Undergoing Lumpectomy With and Without Defect Closure. *Ann Surg Oncol* 2024;31(3):1615-22.



Andreas Giannakou, MD

Assistant Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College

Education: MD, University of Athens Medical School

Residency: University of Pennsylvania and the University of Rochester Medical Center

Fellowships: Massachusetts General Hospital/Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School



Recent Highlights

Leadership

Member, International Committee of the Society of Surgical Oncology for promotion of global initiatives in surgical oncology care and education

Publications

Giannakou A, Gooch J, Gergelis KR, Weiss A. De-escalation of axillary surgery in patients outside Z0011 criteria. *Surgery* 2023;174(2):416-8.

Giannakou A, Kantor O, Park KU, Waks AG, Punglia RS, Dominici LS, Nakhliis F, Mittendorf EA, King TA. Real-World Implications of the SOUND Trial. *Ann Surg Oncol* 2024;31(13):8776-85.

Giannakou A, Dagdeviren C, Ozmen T. Conformable Ultrasound Breast Patch - The Future of Breast Cancer Screening? *Eur J Breast Health* 2025;21(1):90-92.

Dr. Andreas Giannakou, is a board-certified breast surgeon who treats people with breast cancer. He sees patients at Memorial Sloan Kettering Commack on Long Island, and performs surgery at the Josie Robertson Surgery Center in Manhattan.

Dr. Giannakou specializes in advanced breast surgery techniques, including skin-sparing mastectomies, nipple-sparing mastectomies, and oncoplastic surgery. Oncoplastic surgery combines traditional breast cancer surgery with plastic surgery techniques by using hidden incisions and rearranging breast tissue to achieve the best possible cosmetic results for patients.

Dr. Giannakou's research focuses on translating the results of important clinical trials that are potentially practice changing, and on investigating the best and safest ways to potentially implement those findings and incorporate them into everyday clinical practice. His research also focuses on innovation and using the power of artificial intelligence to improve diagnosis, treatment, and care delivery for patients.



Neha Goel, MD, MPH, FACS

Associate Attending, Breast Surgical Service
Chief of Disparities, Department of Surgery
Memorial Sloan Kettering Cancer Center

Education: MD, University of Illinois College of Medicine

Residency: Columbia University Medical Center-New York Presbyterian

Fellowship: Fox Chase Cancer Center



Dr. Neha Goel, is a triple board-certified surgical oncologist and surgeon-scientist who specializes in the surgical management of breast cancer and benign breast diseases, and the use of oncoplastic surgery and nipple-sparing mastectomy to achieve optimal results, including cosmetic outcomes. Dr. Goel sees patients at the MSK Evelyn H. Lauder Breast Center, and performs surgery at Memorial Hospital and the MSK Josie Robertson Surgery Center. She works with a multidisciplinary team of doctors at MSK to ensure that our patients receive the best possible breast cancer treatment and care.

In addition to clinical care, Dr. Goel conducts nationally recognized clinical and translational research on cancer disparities. The Goel Laboratory, “ZIP Code to Genomic Code”, is externally funded by an National Institutes of Health/National Cancer Institute R37, the Breast Cancer Research Foundation, the American Society of Clinical Oncology, the V foundation, the American Surgical Association, and the Society of Surgical Oncology. Through her research, Dr. Goel developed the “social genomic determinants of health,” a field of research that focuses on understanding the biological pathways through which social processes influence cancer biology and outcomes.

The goal of Dr. Goel’s research effort is to develop targeted therapies and cancer control interventions so that all patients can achieve health equity and excellent outcomes. She is a member of the Breast Cancer Research Foundation Health Equity Initiative and also works with the World Health Organization to develop implementation and technical frameworks to assess, strengthen, and scale up services for the early detection and management of breast cancer globally.

Recent Highlights

Grants

National Institutes of Health/National Cancer Institute IR37CA288502-01
Breast Cancer Research Foundation
American Society of Clinical Oncology
V foundation
American Surgical Association
Society of Surgical Oncology

Leadership

Chief of Disparities, Department of Surgery, Memorial Sloan Kettering Cancer Center

Publications

Goel N, Hernandez A, Stoler J. Geospatial Genomics: Operationalizing Multilevel Conceptual Frameworks of Cancer Health Outcomes to Account for Gene-Person-Place Relationships. *J Clin Oncol* 2025;Jco2400751.

Goel N, Hernandez A, Cole SW. Social Genomic Determinants of Health: Understanding the Molecular Pathways by Which Neighborhood Disadvantage Affects Cancer Outcomes. *J Clin Oncol* 2024;42(30):3618-27.

Goel N, Hernandez A, Kwon D, Antoni MH, Cole S. Impact of Neighborhood Disadvantage on Tumor Biology and Breast Cancer Survival. *Ann Surg* 2024 Feb 1;279(2):346-352.

Goel N, Hernandez A, Antoni MH, Kesmodel S, Pinheiro PS, Kobetz E, Merchant N, Cole SW. ZIP Code to Genomic Code: Neighborhood Disadvantage, Aggressive Breast Cancer Biology, and Breast Cancer Outcomes. *Ann Surg* 2024 Jul 1;280(1):1-10.

Goel N, Hernandez A, Mazul A. Neighborhood Disadvantage and Breast Cancer-Specific Survival in the US. *JAMA Netw Open* 2024 Apr 1;7(4):e247336.

Goel N, Hernandez A, Antoni M, Kesmodel S, Figueroa M, Merchant N, Cole S, Kobetz E. Neighborhood Disadvantage and Breast Cancer Disease-Free Survival. *JAMA Netw Open* 2023;6(4):e238908.

Goel N, Hernandez A, Merchant N, Rebbeck T. Translational Epidemiology: Genetic Ancestry in Breast Cancer: What Is the Role of Genetic Ancestry and Socioeconomic Status in Triple-Negative Breast Cancer? *Adv Surg* 2023 Sep;57(1):1-14.

Goldfinger E, Stoler J, Goel N. A multi-scale space-time epidemiological analysis of neighborhood correlates of triple negative breast cancer. *Cancer Epidemiol Biomarkers Prev* 2024 Feb 6;33(2):279-287.

Hernandez A, Goel N. ASO Author Reflections: Moving Towards a Translational Epidemiologic Approach to Genomic Studies. *Ann Surg Oncol* 2023 Nov;30(12):7593-7594.



Alexandra S. Heerdt, MD, MPH, FACS

Attending, Breast Surgical Service
Professor of Surgery, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center

Education: MD, Jefferson Medical College

Residency: The New York Hospital/Cornell Medical Center

Fellowships: Sloan Kettering Institute



Recent Highlights

Endowed Chair

Founder's Chair in Surgical Oncology

Alexandra S. Heerdt, MD, MPH, FACS, is a board-certified surgeon with clinical expertise in diagnosing and treating breast cancer. She holds academic appointments as Attending Surgeon at Memorial Sloan Kettering Cancer Center and Associate Professor of Surgery at Cornell University Weill Medical College, New York NY, and is a surgical faculty member of the Memorial Sloan Kettering Cancer Center Residency Program.

Dr. Heerdt is currently investigating the use of exercise to help control weight gain in women who are undergoing chemotherapy and to help prevent lymphedema in women, as well as the decision making for radiation therapy after breast-conserving surgery in women 70 years of age and older.

Dr. Heerdt's training focus includes a special interest in teaching young physicians to develop their doctor-to-patient and doctor-to-family communications skills in a sensitive, productive, and compassionate manner.

Dr. Heerdt is an active member of local, national, and international societies, including the American College of Surgeons, the Society of Surgical Oncology, the American Society of Breast Surgeons, and the American Society of Clinical Oncology.



Laurie J. Kirstein, MD, FACS

Attending, Breast Surgical Service
Surgical Site Director, MSK Monmouth
Memorial Sloan Kettering Cancer Center
Associate Professor, Weill Cornell Medical College

Education: MD, State University of New York Health Science Center at Brooklyn

Residency: Albert Einstein College of Medicine, Montefiore Medical Center

Fellowships: Massachusetts General Hospital/Brigham and Women's Hospital



Laurie J. Kirstein, MD, FACS, is a board-certified surgical oncologist whose clinical practice and research endeavors are devoted to treating women with breast cancer. She sees patients at our MSK Monmouth facility in Middletown, New Jersey.

Dr. Kirstein has particular expertise in oncoplastic procedures to ensure positive cosmetic outcomes. Dr. Kirstein's research interests focus on quality of life in breast cancer patients. She has led an exploratory/developmental grant (R21) from the National Institutes of Health to create a resource that informs women of their surgical options, provides them with medical facts, debunks myths, and offers women coping strategies with the goal of educating women about their diagnoses, and helping them understand treatment options and recommendations. She was the lead on Breaking Barriers, a multi-year national quality improvement project helping cancer centers identify and overcome barriers to missed active radiation treatment appointments for their patients. Dr. Kirstein is also the principal investigator of a prospective, double-blind, randomized, placebo-controlled trial comparing the installation of bupivacaine versus saline into the wound after unilateral mastectomy without reconstruction.

Recent Highlights

Grants

COMPOSIT, a QI project using an at-home carbon monoxide monitor in the perioperative setting and an intervention for tobacco cessation, \$100,000.

Leadership

Chair, American College of Surgeons Commission on Cancer,

Surgical Site Director, MSK Monmouth

New Initiatives, Same-day mastectomy pathway at MSK Monmouth

Publications

Hogan MP, Horvat JV, Ross DS, Sevilimedu V, Jochelson MS, Kirstein LJ, Goldfarb SB, Comstock CE, Sung JS. Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment. *Breast Cancer Res Treat* 2023;198(2):349-59.

Janczewski LM, Yang AD, Reilly E, Chan K, Coates T, Scarlett S, Hedlund S, Snyder RA, Haffty B, Shelton C, Kirstein LJ. If We Build It, Why They Do Not Come? An American College of Surgeons National Quality Improvement Collaborative to Understand Barriers to Completion of Cancer Treatment. *JCO Oncol Pract* 2025;Op2400745.

Pawloski KR, Srouf MK, Moo TA, Sevilimedu V, Nelson JA, Garcia P, Kirstein LJ, Morrow M, Tadros AB. Timing of Chemotherapy and Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Immediate Reconstruction. *Ann Surg Oncol* 2023;30(5):2897-909.



Minna K. Lee, MD, FACS

Assistant Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Assistant Professor of Surgery, Weill Cornell Medical College

Education: MD, Columbia University College of Physicians and Surgeons

Residency: David Geffen School of Medicine at the University of California, Los Angeles

Fellowship: Cedars-Sinai Medical Center



Minna K. Lee, MD, FACS, is a surgeon who specializes in caring for patients with breast cancer. She works closely with colleagues in medical oncology, radiation oncology, radiology, pathology, and plastic surgery to deliver exceptional care in a compassionate and caring environment. She became a breast surgical oncologist to provide the comprehensive long-term treatment and support needed for people with diseases of the breast. This sentiment is most pronounced in patients who are newly diagnosed with breast cancer.

She is also passionate about using laboratory-based research to improve our understanding of breast cancer biology. Her research focuses on how certain inherited gene mutations that increase a person's risk for breast cancer may also lead to resistance to standard treatments. Insight into these mechanisms of resistance can help us mitigate risk and define patient-specific treatment algorithms.

Recent Highlights

Grants

Society of MSK Research Award

MSK Genomic Instability in Breast
SPOR Developmental Research
Program Award

Department of Surgery Faculty Research
Award

K12 Paul Calabresi Career Development
Award for Clinical Oncology

Leadership

MSK Inherited Breast Cancer Program

Investigator-Initiated Trial

Protocol 23-311: Differential Changes in Ki67 between Carriers and Noncarriers of BRCA2 Mutations with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated with Preoperative Endocrine Therapy.

Publications

Lee MK, Montagna G, Pilewskie ML, Sevilimedu V, Morrow M. Axillary staging is not justified in postmenopausal clinically node-negative women based on nodal disease burden. *Ann Surg Oncol* 2023;30(1):92-97.

Myers SP, Tadros AB, Sevilimedu V, Nelson JA, Le T, Garcia P, Morrow M, Lee MK. Satisfaction and well-being after contralateral prophylactic mastectomy among BRCA mutation carriers and noncarriers: a longitudinal analysis of BREAST-Q domains. *Ann Surg Oncol* 2023;30(12):7116-7123.

Lee MK, Robson ME. Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients? *J Natl Cancer Inst* 2023;115(11):1243-1245.

Myers SP, Sevilimedu V, Barrio AV, Tadros AB, Mamtani A, Robson ME, Morrow M, Lee MK. Mutational status is associated with a higher rate of pathological complete response after neoadjuvant chemotherapy in hormone receptor-positive breast cancer. *Ann Surg Oncol* 2023;30(13):8412-8418.

Myers SP, Bayard S, Tadros AB, Sevilimedu V, Matros E, Nelson JA, Le T, Garcia P, Morrow M, Lee MK. Examining Race and Patient-Reported Outcomes After Contralateral Prophylactic Mastectomy with Reconstruction. *Ann Surg Oncol* 2024;31(2):966-73.

Myers SP, Sevilimedu V, Barrio AV, Tadros AB, Mamtani A, Robson ME, Morrow M, Lee MK. Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers. *NPJ Breast Cancer* 2024;10(1):63.



Anita Mamtani, MD, FACS

Assistant Attending Physician, Breast Surgical Service
Surgical Site Director, MSK Bergen
Memorial Sloan Kettering Cancer Center
Assistant Professor of Surgery, Weill Cornell Medical College

Education: MD, Jefferson Medical College

Residency: Beth Israel Deaconess Medical Center, Harvard Medical School

Fellowship: Memorial Sloan Kettering Cancer Center



Anita Mamtani, MD, FACS, is a breast surgeon who sees patients at our MSK Bergen location in New Jersey.

Her clinical research focus is on the tailoring of axillary surgery and optimizing breast cancer therapies in less-common disease subtypes such as lobular breast cancer. She is the principal investigator of an ongoing trial to evaluate the feasibility of selective use of axillary dissection in clinically node-positive patients (N1) with HR-positive/HER2-negative breast cancer undergoing upfront surgery with planned adjuvant radiation.

Recent Highlights

Investigator initiated trial

Protocol 21-183 Selective Use of ALND in cN1 HR+/HER2- Breast Cancer Patients with 1 or 2 Positive Sentinel Lymph Nodes Undergoing Upfront Breast Surgery and Adjuvant Radiation: A Prospective Study

Leadership

SSO Women in Surgery Committee – Term 2024-2026

Publications

Mamtani A, Sevilimedu V, Le T, Morrow M, Barrio AV. Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy? *Cancer*. 2022 Feb 1;128(3):471-478.

Mamtani A, Sevilimedu V, Vincent A, Morrow M. Local Recurrence is Frequent After Heroic Mastectomy for Classically Inoperable Breast Cancers. *Ann Surg Oncol*. 2022 Feb;29(2):1043-1048.

Mamtani A, Grabenstetter A, Sevilimedu V, Morrow M, Gemignani ML. Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy? *Breast Cancer Res Treat* 2023;197(2):417-23.

Mamtani A, Sjoberg DD, Vincent A, Ehdaie B, Malhotra D, Vickers A, Morrow M. Does a brief surgeon training in negotiation theory principles decrease rates of contralateral prophylactic mastectomy? *Breast Cancer Res Treat* 2023;199(1):119-26.

Myers SP, Sevilimedu V, Barrio AV, Tadros AB, Mamtani A, Robson ME, Morrow M, Lee MK. Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer. *Ann Surg Oncol* 2023;30(13):8412-8.

Zhang YH, Montagna G, Flynn J, Gillespie EF, Mamtani A, Zhang Z, Braunstein LZ, Powell SN, Morrow M, Barrio A, Khan AJ. Outcomes of Breast Cancer Patients with High Volume of Residual Disease Following Neoadjuvant Chemotherapy. *Int J Radiat Oncol Biol Phys* 2023;115(3):622-8.



Debra A. Mangino, DO

Associate Attending Physician, Breast Surgical Service
Memorial Sloan Kettering Cancer Center

Education: DO, New York College of Osteopathic Medicine

Residency: North Shore University Hospital

Fellowship: Memorial Sloan Kettering Cancer Center



Debra A. Mangino, DO, is a board-certified internist with a clinical practice dedicated to the prevention and early detection of breast cancer. As clinical director of Memorial Sloan Kettering's RISE (Risk assessment, Imaging, Surveillance and Education) Program, Dr. Mangino cares for thousands of women at increased risk for breast cancer due to such factors as genetic predisposition and family history of the disease, and biopsy results showing atypical cells.

"Through RISE, I help women make decisions regarding breast cancer screening, strategies for reducing their risk of cancer, and how to maintain their overall health. Ultimately, I hope to improve the overall well-being of my patients by helping to reduce their anxiety about breast cancer."



Giacomo Montagna, MD, MPH

Assistant Attending, Breast Surgical Service
Director, Rare Breast Cancer Program
Memorial Sloan Kettering Cancer Center
Assistant Professor of Surgery, Weill Cornell Medical College

Education: MD, University of Lausanne

Residency: Ente Ospedaliero Cantonale/University Hospital of Basel

Fellowship: Memorial Sloan Kettering Cancer Center



Giacomor Montagna, MD, MPH, is a breast surgical oncologist with specific training in oncoplastic breast surgery, and performs all types of axillary and oncoplastic surgeries, including nipple-sparing mastectomies and oncoplastic lumpectomies. He strives to help all his patients to achieve the best aesthetic result and quality of life after cancer care. His research focuses on de-escalation of axillary surgery, particularly after neoadjuvant chemotherapy, to reduce lymphedema risk, and on the treatment of rare breast tumors, such as metaplastic breast cancer. He sees patients at Memorial Sloan Kettering Cancer Center's Evelyn H. Lauder Center in New York City and at MSK Bergen.

Recent Highlights

Grants

Society of Surgical Oncology
\$100,000 Brooks Brothers Foundation

Leadership

Member of the Breast Disease Site
Work Group

Rare Breast Cancer Program,
Co-Director

Publications

Khan AJ, Montagna G. Contextual Framework for Understanding Treatment De-Escalation in Patients With Breast Cancer. *JCO Oncol Pract* 2025;21(3):278-80.

Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, Barrio AV, van den Bruele AB, Cabioglu N, Sevilimedu V, Rosenberger LH, Hwang ES, Ingham A, Papassotiropoulos B, Nguyen-Sträuli BD, Kurzeder C, Aybar DD, Vorburger D, Matlac DM, Ostapenko E, Riedel F, Fitzal F, Meani F, Fick F, Sagasser J, Heil J, Karanlik H, Dedes KJ, Romics L, Banys-Paluchowski M, Muslumanoglu M, Perez M, Díaz MC, Heidinger M, Fehr MK, Reinisch M, Tukenmez M, Maggi N, Rocco N, Ditsch N, Gentilini OD, Paulinelli RR, Zarhi SS, Kuemmel S, Bruzas S, di Lascio S, Parissenti TK, Hoskin TL, Güth U, Ovale V, Tausch C, Kuerer HM, Caudle AS, Boileau JF, Boughy JC, Kühn T, Morrow M, Weber WP. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy. *JAMA Oncol* 2024;10(6):793-8.

Montagna G, Morrow M, Weber WP. Differences in Sentinel Node Biopsy and Targeted Axillary Dissection Following Neoadjuvant Chemotherapy-Reply. *JAMA Oncol* 2024.

Brown S, Tadros AB, Montagna G, Bell T, Crowley F, Gallagher EJ, Dayan JH. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND). *Front Pharmacol* 2024;15:1457363.

Weber WP, Hanson SE, Wong DE, Heidinger M, Montagna G, Cafferty FH, Kirby AM, Coles CE. Personalizing Locoregional Therapy in Patients With Breast Cancer in 2024: Tailoring Axillary Surgery, Escalating Lymphatic Surgery, and Implementing Evidence-Based Hypofractionated Radiotherapy. *Am Soc Clin Oncol Educ Book* 2024;44(3):e438776..



Tracy-Ann Moo, MD, FACS

Associate Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Surgery, Weill Cornell Medical College

Education: MD, Stony Brook University School of Medicine

Residency: New York Presbyterian Hospital/Weill Cornell Medical College

Fellowship: Memorial Sloan Kettering Cancer Center



Tracy-Ann Moo, MD, FACS, is a surgical oncologist who specializes in caring for women with breast cancer. She has particular expertise in performing nipple-sparing mastectomies for women with breast cancer and those who are at a high risk of developing the disease. She sees patients at the Memorial Sloan Kettering (MSK) Nassau facility on Long Island, NY.

Dr. Moo's clinical research focus is on local control after breast cancer therapy and the use of patient-reported outcomes to improve the quality of breast cancer care.

Recent Highlights

Leadership

Member, Quality Committee, Society of Surgical Oncology

MSK Joint Committee on Provision of Care Task Force

Member, NCCN Breast Cancer Risk Reduction Committee

Publications

Jones VM, Nelson JA, Sevilimedu V, Le T, Allen RJ, Jr., Mehrara BJ, Barrio AV, Capko DM, Heerdt AS, Tadros AB, Gemignani ML, Morrow M, Sacchini V, Moo TA. Impact of Mastectomy Flap Necrosis on Patient-Reported Quality-of-Life Measures After Nipple-Sparing Mastectomy: A Preliminary Analysis. *Ann Surg Oncol* 2024;31(10):6795-803.

Pak LM, Pawloski KR, Sevilimedu V, Kalvin HL, Le T, Tokita HK, Tadros A, Morrow M, Van Zee KJ, Kirstein LJ, Moo TA. How Much Pain Will I Have After Surgery? A Preoperative Nomogram to Predict Acute Pain Following Mastectomy. *Ann Surg Oncol*. 2022 Oct;29(11):6706-6713.

Pawloski KR, Sevilimedu V, Twersky R, Tadros AB, Kirstein LJ, Cody HS 3rd, Morrow M, Moo TA. Association Between Local Anesthetic Dosing, Postoperative Opioid Requirement, and Pain Scores After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. *Ann Surg Oncol*. 2022 Mar;29(3):1737-1745

Pawloski KR, Matar R, Sevilimedu V, Tadros AB, Kirstein LJ, Cody HS, Van Zee KJ, Morrow M, Moo TA. Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. *Ann Surg Oncol*. 2021 Oct;28(10):5507-5512



Monica Morrow, MD, FACS

Chief, Breast Surgical Service
Anne Burnett Windfohr Chair of Clinical Oncology
Memorial Sloan Kettering Cancer Center
Professor of Surgery, Weill Cornell Medical College

Education: MD, Jefferson Medical College

Residency: Medical Center Hospital of Vermont

Fellowship: Memorial Sloan Kettering Cancer Center, Surgical Oncology



Recent Highlights

Awards

Honorary Fellow, Royal College of Surgeons of Ireland

Honorary Fellow, Royal College of Physicians and Surgeons of Glasgow

Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research

John Wayne Clinical Research Award, Society of Surgical Oncology

St. Gallen International Breast Conference Award

Gianni Bonadonna Breast Cancer Award, American Society of Clinical Oncology

Monica Morrow, MD, FACS, is a surgical oncologist with a practice dedicated to the treatment of breast cancer. Her research has focused on how to apply the advances from clinical trials to daily surgical practice. She co-chaired the joint committee of the American College of Surgeons, American College of Radiology, and College of American Pathologists on Standards for Breast-Conserving Therapy for Invasive Breast Cancer and for Ductal Carcinoma In Situ (DCIS) in 2002 and 2007. In 2013 and 2015 Dr. Morrow co-chaired national committees to develop standards for margins in invasive breast cancer and DCIS, which have reduced the number of women requiring more than one lumpectomy. Dr. Morrow has studied the impact of multiple surgeries to obtain clear margins, documented a decrease in the mastectomy rate with adoption of new margin guidelines, and identified surgeon factors associated with performance of axillary dissection. Previous studies have examined patient and surgeon decision making in local therapy, including conflict in decision making and the role of second opinions. Her current research interests involve leveraging the benefits of multidisciplinary therapy to reduce the burden of treatment for patients. Her work has demonstrated an 85% decrease in the use of axillary dissection in patients with node-positive breast cancer undergoing breast conservation when the findings of ACOSOG Z0011 were uniformly applied. She is currently examining issues in local therapy after neoadjuvant chemotherapy and when axillary surgery can be eliminated.

Dr. Morrow has authored more than 600 original articles of peer-reviewed research. In 2012–2013 she was president of the Society of Surgical Oncology. She has been recognized by the American Society of Clinical Oncology with the Gianni Bonadonna Breast Cancer Award, and she was the 2016 recipient of the Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research. In 2019 she received the St. Gallen International Breast Cancer Award, and the John Wayne Clinical Research Award from the Society of Surgical Oncology. She is an honorary fellow of the Royal College of Surgeons of Ireland and the Royal College of Physicians and Surgeons of Glasgow.



Kate Rose Pawloski, MD, MPH

Assistant Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center

Education: MD, Rutgers Robert Wood Johnson Medical School

Residency: Icahn School of Medicine at Mount Sinai

Fellowship: Memorial Sloan Kettering Cancer Center



Kate Rose Pawloski, MD, MPH is a breast surgical oncologist who specializes in the treatment of breast cancer and high-risk benign lesions. In addition to her surgical training, Dr. Pawloski completed a residency in General Preventive Medicine and Public Health. Dr. Pawloski's research interests focus on individualizing breast cancer risk assessment and management, including tailored strategies for primary and secondary prevention.

Recent Highlights

Awards

Veronica Beard Fellowship, Breast Cancer Alliance

Leadership

ASBrS Selected Readings in Breast Surgery Committee; Term: 2025-2027

Publications

Pawloski KR, Barrio AV. Breast surgery after neoadjuvant systemic therapy. *Transl Breast Cancer Res* 2024;5:13.

Pawloski KR, Christian N, Knezevic A, Wen HY, Van Zee KJ, Morrow M, Tadros AB. Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. *Breast Cancer Res Treat* 2020;184(3):873-80.

Pawloski KR, Barrio AV, Gemignani ML, Sevilimedu V, Le T, Dayan J, Morrow M, Tadros AB. Reconstruction in Women with T4 Breast Cancer after Neoadjuvant Chemotherapy: When Is It Safe? *J Am Coll Surg* 2021;233(2):285-93.



George Plitas, MD, FACS

Associate Attending, Breast Surgical Service
Director, Breast Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Surgery, Weill Cornell Medical College

Education: MD, New York University School of Medicine

Residency: New York University Medical Center

Fellowship: Memorial Sloan Kettering Cancer Center



George Plitas, MD, FACS, is a surgical oncologist who specializes in the treatment of patients with breast cancer.

Dr. Plitas is also actively engaged in research involving how the immune system can be used to fight breast cancer. He became interested in immune responses during a three-year research fellowship at Memorial Sloan Kettering Cancer Center where he studied the immune system in the setting of inflammation and infection. During this time, significant advances were made in the understanding of the immune response to cancer. It became increasingly clear that there were many new possibilities to improve the outcome of cancer treatment. These exciting opportunities drove his decision to study immunology in the context of cancer research.

Following a two-year Surgical Oncology Fellowship at Memorial Sloan Kettering Cancer Center, Dr. Plitas joined the surgical faculty of the Breast Service. Working in collaboration with Dr. Alexander Rudensky, chair of the Sloan Kettering Institute's Immunology Program, he conducts research focused on understanding how breast cancers decrease potentially beneficial anti-tumor immune responses.

Recent Highlights

Leadership

Director of Research, Breast Service,
Department of Surgery, Memorial Sloan
Kettering Cancer Center

Publications

Plitas G, Bos PD, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. *J Exper Med* 2013;210(11):2435-66.

Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, Chudakov DM, Rudensky AY. Regulatory T cells exhibit distinct features in human breast cancer. *Immunity* 2016;45(5):1122-34.

Azizi E, Carr AJ, Plitas G (Co-First Author), Cornish AE, Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V, Setty M, Choi K, Fromme RM, Dao P, McKenney PT, Wasti RC, Kadaveru K, Mazutis L, Rudensky AY, Pe'er D. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. *Cell* 2018;174(5):1293-1308.e36s.

Myers SP, Sevilimedu V, Jones VM, Abuhadra N, Montagna G, Plitas G, Morrow M, Downs-Canner SM. Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer. *Ann Surg Oncol* 2024;31(8):5180-8.

Vorstenbosch J, Ghione P, Plitas G, Horwitz S, Kim M, Cordeiro P, Nelson J, McCarthy C. Surgical Management and Long-Term Outcomes of BIA-ALCL: A Multidisciplinary Approach. *Ann Surg Oncol* 2024;31(3):2032-40.

He S, Jin Y, Nazaret A, Shi L, Chen X, Rampersaud S, Dhillon BS, Valdez I, Friend LE, Fan JL, Park CY, Mintz RL, Lao YH, Carrera D, Fang KW, Mehdi K, Rohde M, McFaline-Figueroa JL, Blei D, Leong KW, Rudensky AY, Plitas G, Azizi E. Starfysh integrates spatial transcriptomic and histologic data to reveal heterogeneous tumor-immune hubs. *Nat Biotechnol* 2025;43(2):223-35.



Virgilio S. Sacchini, MD

Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Professor of Surgery, Weill Cornell Medical College

Education: MD, University of Milan Medical School

Residency: National Cancer Institute of Milan

Fellowship: National Cancer Institute of Milan



Recent Highlights

Publications

Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R, Luini A, Viale G, Cassano E, Peradze N, Toesca A, Massari G, Sacchini V, Munzone E, Leonardi MC, Cattadori F, Di Micco R, Esposito E, Sgarella A, Cattaneo S, Busani M, Dessena M, Bianchi A, Cretella E, Ripoll Orts F, Mueller M, Tinterri C, Chahuan Manzur BJ, Benedetto C, Veronesi P; SOUND Trial Group. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. *JAMA Oncol*. 2023 Nov 1;9(11):1557-1564.

Moo TA, Nelson JA, Sevilimedu V, Charyn J, Le TV, Allen RJ, Mehrara BJ, Barrio AV, Capko DM, Pilewskie M, Heerdt AS, Tadros AB, Gemignani ML, Morrow M, Sacchini V. Strategies to avoid mastectomy skinflap necrosis during nipple-sparing mastectomy. *Br J Surg*. 2023 Jun 12;110(7):831-838.

van den Broue AB, Sevilimedu V, Jochelson M, Formenti S, Norton L, Sacchini V. Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program. *NPJ Breast Cancer*. 2022 Jan 21;8(1):14.

Toesca A, Sangalli C, Maisonneuve P, Massari G, Girardi A, Baker JL, Lissidini G, Invento A, Farante G, Corso G, Rietjens M, Peradze N, Gottardi A, Magnoni F, Bottiglieri L, Lazzeroni M, Montagna E, Labo P, Orecchia R, Galimberti V, Intra M, Sacchini V, Veronesi P. A Randomized Trial of Robotic Mastectomy Versus Open Surgery in Women With Breast Cancer or BrCA Mutation. *Ann Surg*. 2022 Jul 1;276(1):11-19.

Virgilio S. Sacchini, MD, is a surgeon who specializes in the treatment of breast cancer. For the past 15 years he has been a co-investigator on clinical trials in Milan, Italy to evaluate conservative surgery and sentinel-node mapping in breast cancer. In Italy, Dr. Sacchini has served as deputy director of the Breast Department at the European Institute of Oncology, an international leader in the study and treatment of breast cancer. Dr. Sacchini was also a clinical coordinator of the Italian Breast Cancer Chemoprevention Study of Tamoxifen, and a clinical investigator on breast cancer trials for the European Organisation for Research and Treatment of Cancer (EORTC).

At Memorial Sloan Kettering Cancer Center, Dr. Sacchini is an active clinical researcher for several studies, including those focusing on the surgical management of patients at high risk for breast cancer. He was a pioneer and is an expert in the technique of nipple-sparing mastectomy, a type of mastectomy that provides excellent cosmetic results. Dr. Sacchini also specializes in oncoplastic surgery, which combines breast cancer surgery and cosmetic surgery with the goal of optimizing final cosmetic outcomes in patients who undergo lumpectomies or mastectomies



Audree B. Tadros, MD, MPH, FACS

Associate Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Assistant Professor, Weill Cornell Medical College

Education: MD, University of Texas Southwestern School of Medicine;
MPH, Icahn School of Public Health at Mount Sinai

Residency: Icahn School of Medicine at Mount Sinai

Fellowship: University of Texas MD Anderson Cancer Center



Audree B. Tadros, MD, MPH, FACS, received her medical degree from the University of Texas Southwestern School of Medicine, completed her general surgical residency at the Icahn School of Medicine at Mount Sinai, and finished her training with a breast surgical oncology fellowship at the University of Texas MD Anderson Cancer Center.

Dr. Tadros's research efforts focus on patient reported outcomes among patients with breast cancer and on optimizing treatment for patients with inflammatory breast cancer patients to improve survival and quality of life.

Recent Highlights

Grants

MSK Interdisciplinary Population Science Research Award

Susan G. Komen Award

Leadership

Michael Zinner Fellow 2022-2023, Surgical Outcomes Club

Inflammatory Breast Cancer Multi-Disciplinary Team Co-Director, Memorial Sloan Kettering Cancer Center

Member, CME Committee, Society of Surgical Oncology

Member, ASBRS Selected Readings Committee, American Society of Breast Surgeons

MSK Surgery Protocol Review Committee, Memorial Sloan Kettering Cancer Center

MSK Clinical Documentation Integrity Committee, Memorial Sloan Kettering Cancer Center

Investigator-Initiated Trials

Protocol #22-136 (Feasibility of Preoperative Radiotherapy in T4 Breast Cancer to Allow for Immediate Reconstruction: a Prospective Study)

Publications

Kim M, Tadros AB, Boe LA, Vingan P, Allen RJ, Jr., Mehrara BJ, Morrow M, Nelson JA. Breast-Conserving Therapy Versus Postmastectomy Breast Reconstruction: Propensity Score-Matched Analysis. *Ann Surg Oncol* 2024;31(12):8030-9.

Rubenstein RN, Nelson JA, Azoury SC, Kim M, Boe LA, Chu JJ, Stern CS, Tadros AB, Mehrara BJ, Matros E. Disparity Reduction in U.S. Breast Reconstruction: An Analysis from 2005 to 2017 Using 3 Nationwide Data Sets. *Plast Reconstr Surg* 2024;154(6):1065e-75e.

Choi JJ, Freedman GM, Guttmann DM, Ahmed K, Gao W, Walker EM, Harris EE, Gonzalez V, Ye J, Nead K, Taunk N, Tadros AB, Dang CT, Daroui P, Novick K. Executive Summary of the American Radium Society Appropriate Use Criteria: Regional Nodal Irradiation for Breast Cancer. *Am J Clin Oncol* 2025;48(3):111-21.

Kim M, Amakiri UO, Wong F, Barnett J, Boe LA, Stern CS, Mehrara BJ, Tadros AB, Nelson JA. Race and Ethnicity Impacts Patient-Reported Outcomes in Implant-Based Breast Reconstruction. *Ann Surg Oncol* 2025;32(1):551-61.

Tadros A, Diskin B, Sevilimedu V, Xu A, Vingan P, Nelson J, Iwai Y, Morrow M, Fayanju OM. Trends in Guideline-Concordant Care for Inflammatory Breast Cancer. *JAMA Netw Open* 2025;8(2):e2454506.

EDUCATION

The Breast Service Fellowship Program at Memorial Sloan Kettering Cancer Center (MSK) is considered one of the top programs of its kind in the country. We attract intelligent, compassionate, and dedicated applicants of the highest caliber. We have a full 5-year approval from the Society of Surgical Oncology (SSO), and our program is a benchmark for others of its type seeking SSO approval.

Our program is structured to ensure that our fellows receive an ideal balance of surgery, clinical care, didactics, and research. Eight of the fellowship months are spent delivering preoperative, intraoperative, and postoperative care. During these rotations, 20% of our fellows' time is spent in the outpatient office setting, diagnosing and treating a wide range of benign and malignant breast conditions. The remaining 80% of our fellows' time is spent in the operating room, where they operate and are taught by renowned surgeons, with the goal of perfecting their surgical and patient care techniques.

MSK's surgical volume is unequalled worldwide. Working closely with the 20 full-time dedicated surgeons of the Breast Service faculty, our fellows learn multiple strategies for problem solving and gain significant experience with uncommon breast problems, which are often seen in our referral practice. Over the past 4 years, the average number of procedures (lumpectomy, mastectomy, sentinel node biopsy, axillary node dissection) performed by each of our fellows, per year, has been more than 580.

Four months are spent on outpatient rotations that complement the surgical training of our fellows, who staff surgical outpatient practices, our high-risk program, and medical oncology, radiation oncology, breast imaging, pathology, and plastic surgery office hours. During these outpatient rotations, fellows are expected to assess patients and discuss treatment options with their attending physicians. This approach provides our fellows with a deep knowledge base in the non-surgical disciplines that is critical to the delivery of modern multidisciplinary breast care. We also require our fellows to gain experience in ultrasound examinations and image-guided biopsies.

In tandem with their medical training, a portion of our fellows' time is dedicated to research. A list of potential research projects is provided to our fellows after they are accepted into the program, and they are encouraged to develop their own research questions. A monthly



research meeting provides a supportive venue for fellows to refine their projects, present their results prior to national presentations, and gain crucial feedback from the entire faculty.

The success of this strategy is clear, given the annual productivity of our fellows, who give oral and poster presentations at the American Society of Clinical Oncology Annual Meeting, the American Society of Breast Surgeons Annual Meeting, the San Antonio Breast Cancer Symposium, and the Society of Surgical Oncology Annual Cancer Symposium, and publish their research in peer-reviewed journals.

MSK provides a formal didactic teaching program for fellows, who present cases at a monthly Multidisciplinary Breast Conference and prepare reviews of key literature for discussion. A small-group Surgical Case Management Series is facilitated by an attending surgeon, and fellows lead detailed discussions of particular cases in an informal setting. A weekly Lecture Series featuring experts in various areas of breast cancer management provides a formal curriculum addressing cutting-edge breast cancer care across disciplines. Moreover, fellows meet monthly for Journal Club with 2 senior surgeons to review significant published research. Once per year, fellows take part in the Society of Surgical Oncology Fellows Institute, and they obtain additional practical experience in ultrasonography and image-guided biopsies. Fellows also undergo COMSKIL training, which fosters sensitive and effective communication with patients and families, especially in difficult care situations. Finally, our fellows complete the MSK Core Curriculum Course, which introduces key topics in clinical research, such as retrospective and prospective research methodology, biostatistics, and clinical trial design and enrollment. Fellows also participate in 2 community outreach events each year, bringing their knowledge to at-risk and vulnerable populations.

As the world's oldest and largest private cancer center, Memorial Sloan Kettering Cancer Center (MSK) has devoted more than a century to patient care and innovative research. At the MSK Evelyn H. Lauder Breast and Imaging Center, our new facility dedicated to the treatment of breast cancer, we average 4,500 new breast cancer patient visits annually. In the field of breast surgery alone at MSK, Breast fellows have performed 6,175 total procedures over the past 2 years. On average, each fellow performed 729 procedures during the 2023-2024 fellowship year

Moreover, our research infrastructure provides crucial support for our fellows. Our database includes over 57,000 breast cancer cases, and we have a team of 11 research managers and staff to assist our fellows in conducting their research.

In 2023–2024, our fellows gave 12 oral and poster presentations at major oncology conferences, and authored 5 original research articles published in peer-reviewed journals.

Finally, our faculty, consisting of 20 full-time academic clinicians who specialize in caring for breast cancer patients, are leaders in the field who have conducted transformational research and developed new standards of care. Ongoing interaction with these mentors provides our fellows with a degree of academic rigor that makes them highly sought after upon graduation for faculty positions across the United States and around the world.

The defined goals and objectives of the Breast Service Fellowship Program include:

1. Learning how to screen, diagnose, and treat benign and malignant breast disease
2. Learning all operative techniques for the treatment of breast cancer
3. Mastering techniques for all types of mastectomy, including nipple-sparing mastectomy
4. Performing all types of lumpectomy, including seed localization
5. Gaining a foundational understanding of oncoplastic techniques and breast reconstruction techniques
6. Learning how to perform sentinel node biopsy and axillary node dissection
7. Gaining exposure to all breast modalities, including ultrasound
8. Managing all aspects of preoperative and postoperative patient care
9. Learning how to identify lymphedema
10. Learning the basic principles of cancer biology, genetics, biostatistics, and epidemiology
11. Learning how to integrate an evidence-based approach to patient care
12. Understanding the multidisciplinary delivery of breast cancer care
13. Learning how to formulate a research hypothesis, collect and analyze data, and write a peer-reviewed journal article of original research
14. Learning how to present at scientific meetings
15. Gaining exposure to medical oncology, radiation oncology, plastic surgery, pathology, and radiology
16. Learning how to work effectively as a member or leader of a health care team
17. Advocating for quality patient care and optimal patient care systems

Operative Experience

The surgical experience at MSK is unparalleled. Fellows participate as surgeons or first assistants in the majority of the procedures. This case load is large enough to accommodate and train each fellow in a senior capacity. Breast Surgery nurse practitioners and physician assistants work full time on the service and assist in the operating room, with inpatient perioperative care, and in the outpatient clinic.

The following table summarizes the average number of cases performed by fellows in each fellowship year:

Table: Fellowship Year Averages (2019-2024)							
Fellowship Year	BCS	Mastectomy	Chest Wall Excision	Modified Radical Mastectomy	SLNBx	ALND	Total
2019-2020	186	102	2	18	164	33	506
2020-2021	228	117	2	8	194	22	548
2021-2022	228	117	2	8	194	22	548
2022-2023	206	107	7	4	166	20	510
2023-2024	281	227	5	4	187	22	725
Total	1129	670	18	42	905	119	2837
Average	226	134	4	8	181	24	567

Rotation Schedule

Each fellow spends eight months on inpatient rotations. There are four surgical teams, with each team consisting of three attending surgeons together with one fellow. Four days/week are spent in the operating room, and the fellow operates with each member of the team. The additional day of the week is spent in the outpatient setting with a team attending.

Each fellow spends four months on outpatient rotations.

Ambulatory Experience

Outpatient A:	Medical Oncology 2 weeks / Plastic Surgery 1 week / Vacation 1 week
Outpatient B:	Radiation Oncology 1 week / Radiology 2 weeks / RISE and Genetics 1 week
Outpatient C:	Pathology 1 week / Surgical Outpatient Clinics 2 weeks / Vacation 1 week
Outpatient D:	Research 2 weeks / Psycho-Oncology and Rehabilitation Medicine 2 weeks



The outpatient rotations are divided into four months of outpatient core curriculum rotations:

1. Multidisciplinary Breast Conference: a weekly conference attended by DMT members. Fellows present and prepare cases for discussion
2. Surgical Case Management Series: one attending surgeon and the fellows discuss cases and case management
3. Didactic lecture series: a weekly lecture series on core curriculum topics in breast surgery
4. Journal Club: a monthly meeting emphasizing critical review of the latest literature
5. Department of Surgery Grand Rounds: a weekly departmental meeting focusing on surgical oncology topics
6. Society of Surgical Oncology Fellows Institute (November)
7. COMSKIL Training: an annual symposium emphasizing culturally appropriate styles of communication to use in dealing with families and patients. Interview and patient interaction skills are taught.
8. MSK Core Curriculum Courses: courses focusing on research methodology, biostatistics, clinical trial development, and patient enrollment
9. Breast Surgery Research Conference: a monthly meeting in which fellows are responsible for discussing proposed research and upcoming presentations at national meetings

International Breast Surgical Oncology Fellowship Position

In 2016 we introduced our first International Fellow position. The goal of this position is to train future international leaders who desire to advance breast cancer surgery care delivery and research worldwide.

The current program is a one-year position offered to fully trained residents who have completed residency training overseas and plan to return to their home country with advanced skills and surgical expertise. The International Fellow is integrated into

our program, and has the same experience both in the inpatient and outpatient rotations as our Society of Surgical Oncology fellows. Emphasis is placed on surgical training as well as research. As one of the largest fellowship programs, there is clearly the opportunity for camaraderie and ongoing collaborative professional relationships with co-fellows as well as faculty. We expect this program to successfully advance the field of breast surgery on an international level.

1. Pilewskie M, Zabor EC, Gilbert E, Stempel M, Petruolo O, Mangino D, Robson M, Jochelson MS. Differences between screen-detected and interval breast cancers among BRCA mutation carriers. *Breast Cancer Res Treat* 2019;175(1):141-8.
2. Botty Van den Bruele A, Gemignani ML. Management of ipsilateral supernumerary nipple at time of breast cancer diagnosis. *Breast J* 2020;26(10):2042-4.
3. Crown A, Muhsen S, Zabor EC, Sevilimedu V, Kelvin J, Goldfarb SB, Gemignani ML. Does Use of Neoadjuvant Chemotherapy Affect the Decision to Pursue Fertility Preservation Options in Young Women with Breast Cancer? *Ann Surg Oncol* 2020;27(12):4740-9.
4. Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M. Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy. *Ann Surg Oncol* 2020;27(11):4515-22.
5. Montagna G, Morrow M. Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients. *Expert Rev Anticancer Ther* 2020;20(3):159-66.
6. Montagna G, Sevilimedu V, Fornier M, Jhaveri K, Morrow M, Pilewskie ML. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery? *Ann Surg Oncol* 2020;27(12):4702-10.
7. Barrio AV, Montagna G, Mamtani A, Sevilimedu V, Edelweiss M, Capko D, Cody HS, 3rd, El-Tamer M, Gemignani ML, Heerdt A, Kirstein L, Moo TA, Pilewskie M, Plitas G, Sacchini V, Sclafani L, Tadros A, Van Zee KJ, Morrow M. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event. *JAMA Oncol* 2021;7(12):1851-5.
8. Berger ER, Iyengar NM. Obesity and Energy Balance Considerations in Triple-Negative Breast Cancer. *Cancer J* 2021;27(1):17-24.
9. Botty van den Bruele A, Ferraro E, Sevilimedu V, Hogan MP, Javed-Tayyab S, Le T, Fornier MN, Morrow M, Sacchini V. Does preoperative MRI accurately stratify early-stage HER2+ breast cancer patients to upfront surgery vs neoadjuvant chemotherapy? *Breast Cancer Res Treat* 2021;189(2):307-15.
10. Botty Van den Bruele A, Lavery J, Plitas G, Pilewskie ML. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy. *Ann Surg Oncol* 2021;28(2):968-74.
11. Chen I, Botty Van den Bruele AM, Gillespie EF, Mueller BA, Xu AJ, Cuaron J, Khan AJ, McCormick B, Cahlon O, Powell SN, Cody H, Braunstein LZ. Salvage of locally recurrent breast cancer with repeat breast conservation using 45 Gy hyperfractionated partial breast re-irradiation. *Breast Cancer Res Treat* 2021;188(2):409-14.
12. Crown A, Gonen M, Le T, Morrow M. Does Failure to Achieve Pathologic Complete Response with Neoadjuvant Chemotherapy Identify Node-Negative Patients Who Would Benefit from Postmastectomy Radiation or Regional Nodal Irradiation? *Ann Surg Oncol* 2021;28(3):1328-35.
13. Crown A, Sevilimedu V, Morrow M. Palpable Adenopathy Does Not Indicate High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer. *Ann Surg Oncol* 2021;28(11):6060-8.
14. Montagna G, Morrow M. Breast-conserving Surgery Without Radiation Therapy for Invasive Cancer. *Clin Breast Cancer* 2021;21(2):112-9.
15. Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery? *Ann Surg Oncol* 2021;28(1):287-94.
16. Tringale KR, Berger ER, Heerdt AS, Braunstein LZ. Reply to Impact of radiation and hormonal therapy on the locoregional recurrence of elderly breast cancer: Are these necessary after breast-conserving surgery? *Cancer* 2021;127(15):2809-10.
17. Tringale KR, Berger ER, Sevilimedu V, Wen HY, Gillespie EF, Mueller BA, McCormick B, Xu AJ, Cuaron JJ, Cahlon O, Khan AJ, Powell SN, Morrow M, Heerdt AS, Braunstein LZ. Breast conservation among older patients with early-stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy. *Cancer* 2021;127(11):1749-57.
18. Van den Bruele AB, Chen I, Sevilimedu V, Le T, Morrow M, Braunstein LZ, Cody HS, 3rd. Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy. *Breast Cancer Res Treat* 2021;187(1):105-12.
19. Zhang JQ, Plitas G. Immunotherapeutic strategies in breast cancer: A clinical update. *J Surg Oncol* 2021;123(3):710-7.
20. Barrio AV, Montagna G, Morrow M. Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?-Reply. *JAMA Oncol* 2022;8(6):1.
21. Crown A, Muhsen S, Sevilimedu V, Kelvin J, Goldfarb SB, Gemignani ML. Fertility Preservation in Young Women with Breast Cancer: Impact on Treatment and Outcomes. *Ann Surg Oncol* 2022;29(9):5786-96.
22. Mallory MA, Whiting K, Park A, Gönen M, Gilbert E, King TA, Pilewskie ML. Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. *Breast Cancer Res Treat* 2022;194(1):137-48.
23. Matar R, Crown A, Sevilimedu V, Goldfarb SB, Gemignani ML. Timing of Presentation and Outcomes of Women with Stage IV Pregnancy-Associated Breast Cancer (PABC). *Ann Surg Oncol* 2022;29(3):1695-702.
24. Montagna G, Lee MK, Sevilimedu V, Barrio AV, Morrow M. Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy? *Ann Surg Oncol* 2022;29(10):6133-9.
25. Montagna G, Zhang J, Sevilimedu V, Charyn J, Abbate K, Gomez EA, Mehrara B, Morrow M, Barrio AV. Risk Factors and Racial and Ethnic Disparities in Patients With Breast Cancer-Related Lymphedema. *JAMA Oncol* 2022;8(8):1195-200.
26. Mrdutt M, Heerdt A, Sevilimedu V, Mamtani A, Barrio A, Morrow M. Margin Width and Local Recurrence in Patients Undergoing Breast Conservation After Neoadjuvant Chemotherapy. *Ann Surg Oncol* 2022;29(1):484-92.
27. Pak LM, Morrow M. Addressing the problem of overtreatment in breast cancer. *Expert Rev Anticancer Ther* 2022;22(5):535-48.
28. Pak LM, Pawloski KR, Sevilimedu V, Kalvin HL, Le T, Tokita HK, Tadros A, Morrow M, Van Zee KJ, Kirstein LJ, Moo TA. How Much Pain Will I Have After Surgery? A Preoperative Nomogram to Predict Acute Pain Following Mastectomy. *Ann Surg Oncol* 2022;29(11):6706-13.
29. Shubeck S, Sevilimedu V, Berger E, Robson M, Heerdt AS, Pilewskie ML. Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy. *Ann Surg Oncol* 2022;29(8):4706-13.
30. Shubeck SP, Morrow M, Dossett LA. De-escalation in breast cancer surgery. *NPJ Breast Cancer* 2022;8(1):25.
31. Srour MK, Tadros AB, Sevilimedu V, Nelson JA, Cracchiolo JR, McCready TM, Silva N, Moo TA, Morrow M. Who Are We Missing: Does Engagement in Patient-Reported Outcome Measures for Breast Cancer Vary by Age, Race, or Disease Stage? *Ann Surg Oncol* 2022;29(13):7964-73.
32. van den Bruele AB, Sevilimedu V, Jochelson M, Formenti S, Norton L, Sacchini V. Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program. *NPJ Breast Cancer* 2022;8(1):14.
33. Verdial FC, Mamtani A, Pawloski KR, Sevilimedu V, D'Alfonso TM, Zhang H, Gemignani ML, Barrio AV, Morrow M, Tadros AB. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer. *Ann Surg Oncol* 2022;29(6):3810-9.
34. Weber WP, Shaw J, Pusic A, Wyld L, Morrow M, King T, Mátrai Z, Heil J, Fitzal F, Potter S, Rubio IT, Cardoso MJ, Gentilini OD, Galimberti V,

- Sacchini V, Rutgers EJT, Benson J, Allweis TM, Haug M, Paulinelli RR, Kovacs T, Harder Y, Gulluoglu BM, Gonzalez E, Faridi A, Elder E, Dubsky P, Blohmer JU, Bjelic-Radisic V, Barry M, Hay SD, Bowles K, French J, Reitsamer R, Koller R, Schrenk P, Kauer-Dorner D, Biazus J, Brenelli F, Letzkus J, Saccilotto R, Joukainen S, Kauhanen S, Karhunen-Enckell U, Hoffmann J, Kneser U, Kühn T, Kontos M, Tampaki EC, Carmon M, Hadar T, Catanuto G, Garcia-Etienne CA, Koppert L, Gouveia PF, Lagergren J, Svensjö T, Maggi N, Kappos EA, Schwab FD, Castrezana L, Steffens D, Krol J, Tausch C, Günthert A, Knauer M, Katapodi MC, Bucher S, Hauser N, Kurzeder C, Mucklow R, Tsoutsou PG, Sezer A, Çakmak GK, Karanlik H, Fairbrother P, Romics L, Montagna G, Urban C, Walker M, Formenti SC, Gruber G, Zimmermann F, Zwahlen DR, Kuemmel S, El-Tamer M, Vrancken Peeters MJ, Kaidar-Person O, Gnant M, Poortmans P, de Boniface J. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. *Breast* 2022;63:123-39.
35. Williams AD, Dang CT, Sevilimedu V, Morrow M, Barrio AV. Neoadjuvant Chemotherapy for Breast Cancer In the Elderly: Are We Accomplishing Our Treatment Goals? *Ann Surg Oncol* 2022;29(13):8002-11.
 36. Williams AD, Khan AJ, Sevilimedu V, Barrio AV, Morrow M, Mamtani A. Omission of Intraoperative Frozen Section May Reduce Axillary Overtreatment Among Clinically Node-Negative Patients Having Upfront Mastectomy. *Ann Surg Oncol* 2022;29(13):8037-43.
 37. Williams AD, Pawloski KR, Wen HY, Sevilimedu V, Thompson D, Morrow M, El-Tamer M. Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age. *Breast Cancer Res Treat* 2022;196(3):565-70.
 38. Zhang JQ, Montagna G, Sevilimedu V, Abbate K, Charyn J, Mehrara B, Morrow M, Barrio AV. Longitudinal Prospective Evaluation of Quality of Life After Axillary Lymph Node Dissection. *Ann Surg Oncol* 2022.
 39. Beck AC, Bayard S, Plitas G, Sevilimedu V, Kuba MG, Garcia P, Morrow M, Tadros AB. Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence? *Ann Surg Oncol* 2023;30(10):6061-9.
 40. Beck AC, Morrow M. Axillary lymph node dissection: Dead or still alive? *Breast* 2023;69:469-75.
 41. Crown A, McCartan D, Curry MA, Patil S, Kamer S, Goldfarb S, Gemignani ML. Pregnancy-associated breast cancer: does timing of presentation affect outcome? *Breast Cancer Res Treat* 2023;198(2):283-94.
 42. Matar-Ujvary R, Haglich K, Flanagan MR, Fuzesi S, Sevilimedu V, Nelson JA, Gemignani ML. The Impact of Breast-Conserving Surgery Re-excision on Patient-Reported Outcomes Using the BREAST-Q. *Ann Surg Oncol* 2023;30(9):5341-9.
 43. Myers SP, Sevilimedu V, Barrio AV, Tadros AB, Mamtani A, Robson ME, Morrow M, Lee MK. Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer. *Ann Surg Oncol* 2023;30(13):8412-8.
 44. Myers SP, Tadros AB, Sevilimedu V, Nelson JA, Le T, Garcia P, Morrow M, Lee MK. Satisfaction and Well-Being After Contralateral Prophylactic Mastectomy Among BRCA Mutation Carriers and Noncarriers: A Longitudinal Analysis of BREAST-Q Domains. *Ann Surg Oncol* 2023;30(12):7116-23.
 45. Pak LM, Matar-Ujvary R, Verdial FC, Haglich KA, Sevilimedu V, Nelson JA, Gemignani ML. Long-Term Patient-Reported Outcomes Comparing Oncoplastic Breast Surgery and Conventional Breast-Conserving Surgery: A Propensity Score-Matched Analysis. *Ann Surg Oncol* 2023;30(12):7091-8.
 46. Palmquist E, Limberg J, Chu JJ, White C, Baser RE, Sevilimedu V, Pawloski KR, Garcia P, Nelson JA, Moo TA, Morrow M, Tadros AB. Patient-Reported Outcome Measures for Patients Who Have Clinical T4 Breast Cancer Treated via Mastectomy with and Without Reconstruction. *Ann Surg Oncol* 2023;30(1):115-21.
 47. Pawloski KR, Srour MK, Moo TA, Sevilimedu V, Nelson JA, Garcia P, Kirstein LJ, Morrow M, Tadros AB. Timing of Chemotherapy and Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Immediate Reconstruction. *Ann Surg Oncol* 2023;30(5):2897-909.
 48. Diskin B, Sevilimedu V, Morrow M, Van Zee K, Cody HS, 3rd. Management of Ipsilateral Breast Tumor Recurrence Following Breast Conservation Surgery for Ductal Carcinoma In Situ: A Data-Poor Zone. *Ann Surg Oncol* 2024;31(13):8843-7.
 49. Heller DR, Axelrod B, Sevilimedu V, Morrow M, Mehrara BJ, Barrio AV. Quality of Life After Axillary Lymph Node Dissection Among Racial and Ethnic Minority Women. *JAMA Surg* 2024;159(6):668-76.
 50. Jones VM, Nelson JA, Sevilimedu V, Le T, Allen RJ, Jr., Mehrara BJ, Barrio AV, Capko DM, Heerdt AS, Tadros AB, Gemignani ML, Morrow M, Sacchini V, Moo TA. Impact of Mastectomy Flap Necrosis on Patient-Reported Quality-of-Life Measures After Nipple-Sparing Mastectomy: A Preliminary Analysis. *Ann Surg Oncol* 2024;31(10):6795-803.
 51. Mai N, Myers S, Shen S, Downs-Canner S, Robson M, Norton L, Chen Y, Traina T, Abuhadra N. Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer. *NPJ Breast Cancer* 2024;10(1):39.
 52. Myers SP, Aviki E, Sevilimedu V, Thom B, Gemignani ML. Financial Toxicity Among Women with Breast Cancer Varies by Age and Race. *Ann Surg Oncol* 2024;31(12):8040-7.
 53. Myers SP, Bayard S, Tadros AB, Sevilimedu V, Matros E, Nelson JA, Le T, Garcia P, Morrow M, Lee MK. Examining Race and Patient-Reported Outcomes After Contralateral Prophylactic Mastectomy with Reconstruction. *Ann Surg Oncol* 2024;31(2):966-73.
 54. Myers SP, Gilliland J, Goldfarb SB, Gemignani ML. Perspectives of Young Women with Breast Cancer: Patient Experiences Indicate Opportunities to Improve Treatment. *J Adolesc Young Adult Oncol* 2024.
 55. Myers SP, Sevilimedu V, Barrio AV, Tadros AB, Mamtani A, Robson ME, Morrow M, Lee MK. Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers. *NPJ Breast Cancer* 2024;10(1):63.
 56. Myers SP, Sevilimedu V, Jones VM, Abuhadra N, Montagna G, Plitas G, Morrow M, Downs-Canner SM. Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer. *Ann Surg Oncol* 2024;31(8):5180-8.
 57. Palmquist E, Sevilimedu V, Garcia P, Le T, Zhang X, Pinker-Domenig K, Hanna MG, Nelson JA, Morrow M, El-Tamer M. Patient-Reported Outcomes in Patients Undergoing Lumpectomy With and Without Defect Closure. *Ann Surg Oncol* 2024;31(3):1615-22.
 58. Pawloski KR, Barrio AV. Breast surgery after neoadjuvant systemic therapy. *Transl Breast Cancer Res* 2024;5:13.
 59. Matar-Ujvary R, Sevilimedu V, Morrow M. Are Clinically Node-Negative Patients with a Positive Preoperative Axillary Lymph Node Biopsy Appropriate Candidates for Sentinel Lymph Node Biopsy? *Ann Surg Oncol* 2025;32(1):92-7.
 60. Perry LM, Sevilimedu V, Polidoro N, Abuhadra N, Morrow M, Plitas G, Downs-Canner S. Predictors of Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer. *Ann Surg Oncol* 2025.
 61. Tadros A, Diskin B, Sevilimedu V, Xu A, Vingan P, Nelson J, Iwai Y, Morrow M, Fayanju OM. Trends in Guideline-Concordant Care for Inflammatory Breast Cancer. *JAMA Netw Open* 2025;8(2):e2454506.

GRADUATES OF THE BREAST SERVICE FELLOWSHIP PROGRAM (1995-2024)

1995–1996

Brian O'Hea, MD, FACS
Chief, Breast Surgery Division
Leader, Breast Care Team
Director, Carol M. Baldwin Breast Care Center
Division of Breast and Oncologic Surgery
Department of Surgery,
Health Sciences Center, T18-060
Renaissance School of Medicine,
Stony Brook University

1996–1997

E. Shelley Hwang, MD, MPH
Duke University Medical Center

1997–1998

Prof. Arnold Hill, MCh, FRCSI
Dean of Medical Programmes and Professor of Surgery
Royal College of Surgeons in Ireland (RCSI)
Education & Research Centre
Beaumont Hospital

1998–1999

Laura Hoque, MD
Deceased

Mary Gemignani, MD, MPH
Chief of Breast Surgery
Department of Surgery
Perlmutter Cancer Center
NYU Langone Health
Professor of Surgery
NYU Grossman School of Medicine

1999–2000

Stephanie Bernik, MD, FACS
Chief of Breast Service
Mount Sinai West

2000–2001

Susan K. Boolbol, MD, FACS
System Chief,
Breast Surgical Oncology and Breast Program
Nuvance Health
Chief, Breast Surgical Oncology and Breast Program
Dyson Breast Center at Vassar Brothers Medical Center
Anna M. Derossis, MD, MHPE, FRCSC, FACS
Deceased

2001–2002

Eleni Tousimis, MD
Chief of Breast Surgery
MedStar Georgetown University Hospital
Pasquerilla Healthcare Center (PHC)
Archana Ganaraj, MD
Texas Health Presbyterian Hospital of Dallas

2002–2003

Tari A. King, MD
Vice Chair for Multidisciplinary Oncology
Department of Surgery
Chief, Division of Breast Surgery
Brigham and Women's Hospital
Dana-Farber/Brigham Cancer Center
Anne E. Dyson Professor of Surgery
in the Field of Women's Cancers
Harvard Medical School
May Lynn Quan, MD, MSc, FRCSC
Professor of Surgery and Oncology
University of Calgary
Medical Director, Calgary Breast Health Program
Foothills Medical Centre
Donna-Marie Manasseh, MD, FACS
Chief, Breast Surgery
Director, Maimonides Breast Cancer Program
Maimonides Breast Cancer Center

2003–2004

Michelle Specht, MD
Assistant Attending, Department of Surgery
Massachusetts General Hospital
Division of Surgical Oncology

Jane E. Mendez, MD, FACS
Chief of Breast Surgery
Miami Cancer Institute

Arpana Naik, MD
Associate Professor, Department of Surgery
Medical Director, The Breast Center at
OHSU Oregon Health and Science University

2004–2005

Claire Buchanan, MD, FACS
Physician
Fred Hutch
Assistant Professor, General Surgery
University of Washington School of Medicine
Fred Hutchinson Cancer Center

Paniti Sukumvanich, MD
Associate Professor
Fellowship Director, Gynecologic Oncology
Fellowship Program
Division of Gynecologic Oncology
Department of OB/GYN
Women's Hospital/University of Pittsburgh
Medical Center

Anne O'Neill, MD
Las Vegas Surgical Associates

2005–2006

Carlos A. Garcia-Etienne, MD
Breast Surgical Oncology/Oncoplastic Surgery Breast
Center, Ospedale Santa Chiara, Trent
Laurie Flynn, MD, FACS
Oklahoma Cancer Specialists and Research Institute

Mary Jo Wright, MD
Chief, Breast Surgery, Tulane
Medical Director, Breast Center
Medical Center of Louisiana New Orleans

2006–2007

Andrea V. Barrio, MD
Breast Service, Department of Surgery
Memorial Sloan Kettering Cancer Center
Sarah McLaughlin, MD
Mayo Clinic Jacksonville General Surgery
Karl J. Sweeney, MD
BreastCheck, Western Unit
Galway University Hospital

Jeanne Yu, MD
Massachusetts General Hospital
Department of Surgical Oncology

2007–2008

Everett J. Bonner, Jr., MD, FACS
Chairman, Breast Service
Baton Rouge General Hospital
Assistant Clinical Professor of Surgery,
Tulane University School of Medicine

Alice Chung, MD, FACS
Assistant Professor of Surgery
Associate Program Director
Breast Oncology Fellowship
Division of Surgical Oncology
Cedars-Sinai Medical Center

Amer Karam, MD
Associate Professor
Stanford Hospital and Clinics
Department of Obstetrics and Gynecology

Nicole Sroka, MD
Piedmont Fayette Hospital

2008–2009

Michelle Azu, MD, FACS
Assistant Professor of Surgery
Columbia University
Director of Breast Surgical Services
NYP-Lawrence Hospital Associate Director,
Breast Disease Management Team
NYP-Lawrence Hospital

Matthew S. Pugliese, MD
University Surgical Oncology

Shannon N. Tierney, MD, MS
Augusta Health Breast Surgery

Lisa S. Wiechmann, MD
Assistant Professor
Breast Surgical Oncology
Columbia Presbyterian Hospital

2009–2010

Sara A. Bloom, MD
Inova Breast Care Center

Lydia W. Choi, MD
Assistant Professor of Surgery
Wayne State School of Medicine
Barbara Ann Karmanos Cancer Institute

Shicha Kumar, MD
Rutgers Cancer Institute of New Jersey

Jennifer L. Marti, MD Breast Surgery
Tisch Cancer Institute
Mount Sinai Hospital

2010–2011

John Mitchel Barry, MD
Consultant General/Breast Surgeon
Mater Misericordiae University Hospital

Kshama Jaiswal, MD
Associate Professor
Associate Program Director
University of Colorado General Surgery Residency
University of Colorado at Denver
Anschutz School of Medicine

Bridget Oppong, MD
Associate Professor of Surgery
Department of Surgery
Division of Surgical Oncology
Breast Surgical Oncology Fellowship Deputy Director
Deputy Director, Center for Cancer Health Equity
(CCH) James Comprehensive Cancer Center
Stephanie Spielman Comprehensive Breast Center

Prof. Dr. Walter Paul Weber
Chief of Breast Surgery
Chair of Department "Breast, Abdomen, Pelvis"
University Hospital Basel

2011–2012

Daniel X. Choi, MD, FACS
Associate Attending
Breast Service, Department of Surgery
Memorial Sloan Kettering Cancer Center

Manuela Junqueira Powell, MD, CPC
Mindset Coach

Jennifer Casher Lehman, MD
Associate Chief
Mount Sinai West / Mount Sinai
Union Square

Catherine E. Pesce, MD
Chief, Division of Surgical Oncology
Program Director, Breast Surgical Oncology Fellowship
NorthShore University HealthSystem
Clinical Associate Professor,
University of Chicago Pritzker
School of Medicine

2012–2013

Tracy-Ann Moo, MD
Breast Service, Department of Surgery
Memorial Sloan Kettering Cancer Center

James Oliver (Seamus) Murphy, MD, FRCSI
Consultant Breast & General Surgeon
University Hospital Waterford

Melissa L. Pilewskie, MD
Associate Professor of Surgery
Director of Breast Care
University of Michigan

Lynn T. Dengel, MD, MSc
Virginia Breast Care
Charlottesville, VA
University of Virginia
Department of Surgery

2013–2014

Aidan T. Manning, MD
Consultant Breast and General Surgeon
University Hospital Waterford
Dunmore Road

Cindy Brown Matsen, MD
Associate Professor, Department of Surgery
University of Utah
Huntsman Cancer Hospital

Julie A. O'Brien, MD
Assistant Clinical Professor of Surgery
Tufts University School of Medicine
Lahey Clinic and Medical Center
Director, Lahey Comprehensive Breast Health Center

Stacy K. Ugras, MD
Assistant Professor of Surgery, Department of Surgery
New York-Presbyterian/
Columbia University Medical Center

2014–2015

David N. Anderson, MD
Assistant Professor of Clinical Surgery
Division of Endocrine and Oncologic Surgery
Perelman School of Medicine

Maria Karsten, MD
Leitende Oberärztin des Brustzentrum
Charité—Universitätsmedizin Berlin

Starr Mautner, MD
Breast Surgical Oncologist
Baptist Health South Florida
The Miami Cancer Institute

Preeti Subhedar, MD
Associate Professor
Division of Surgical Oncology Winship Cancer Center
Emory University School of Medicine

2015–2016

Patricia A. Cronin, MD, FRCS
Associate Professor of Surgery
Division of Surgical Oncology
Mayo Clinic Arizona

Damian McCartan, MD
Consultant Breast and General Surgeon
St Vincent's University Hospital Dublin

Laura H. Rosenberger, MD
Associate Professor
Duke University
Department of Surgery

Joseph J. Weber, MD
Breast Surgical Oncologist
Medical Director, Breast Center of Excellence at
Aurora Medical Center Grafton
Assistant Clinical Professor of Surgery,
Medical College of Wisconsin
Clinical Adjunct Assistant Professor,
University of Wisconsin
School of Medicine and Public Health

2016–2017

Lori Gentile, MD
Novant Health
Carolina Surgical Oncology

Megan Miller, MD
Assistant Professor
Division of Surgical Oncology
Department of Surgery
Case Western Reserve University School of Medicine
University Hospitals
Seidman Cancer Center

Shirin Muhsen, MD
Chief Quality Officer
General Surgeon
Doha, Qatar

Elizabeth Shurell, MD, MPhil
Breast Surgical Oncologist
Kaiser Permanente
San Francisco Medical Center

Siun Walsh, MD
Mater Misericordiae University Hospital

2017–2018

Jennifer Baker, MD
Assistant Professor
Division of Breast Surgery,
Department of General Surgery University of
California Los Angeles (UCLA)

Stephanie Downs-Canner, MD
Assistant Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Director, Breast Surgery Fellowship Program

Meghan R. Flanagan, MD, MPH
Assistant Professor
Division of Surgical Oncology
Department of Surgery
University of Washington School of Medicine
Assistant Member
Division of Public Health Sciences
Fred Hutchinson Cancer Center

Anya M. Romanoff, MD
Assistant Professor
Department of Surgery
Division of Surgical Oncology
Health System Design and Global Health
The Icahn School of Medicine at Mount Sinai

2018–2019

Nicole Christian, MD
Assistant Professor
Division of Surgical Oncology,
Department of Surgery
University of Colorado School of Medicine

Anita Mamtani, MD
Breast Service, Department of Surgery
Memorial Sloan Kettering Cancer Center

Christina Minami, MD, MS
Division of Breast Surgery
Brigham and Women's Hospital/Dana-Farber
Cancer Institute

Monica G. Valero, MD
Assistant Professor
Breast Surgical Oncology
Yale School of Medicine

2019–2020

Elizabeth Berger, MD, MS
Assistant Professor
Division of Surgical Oncology
Department of Surgery
Yale University School of Medicine

Astrid Botty van den Bruele, MD
Breast Surgical Oncologist
Assistant Professor of Surgery
Associate Program Director
of the Breast Surgical Oncology Fellowship
Duke University Hospital
Duke Regional Hospital

Angelena Crown, MD, FACS
Clinical Instructor
University of Washington Department of Surgery
Deputy Director of Breast Surgery
Director of Breast Surgery Research True Family
Women's Cancer Center Swedish Cancer Institute

Melissa Anne Mallory, MD
Assistant Professor of Surgery,
Department of Breast Oncology
Moffitt Cancer Center

Oriana Petruolo, MD
Breast Surgical Oncology
Hackensack University

2020–2021

Sarah Shubeck, MD, MS
Assistant Professor
Department of Surgery
University of Chicago

Giacomo Montagna, MD, MPH
Breast Service, Department of Surgery
Memorial Sloan Kettering Cancer Center

Mary Megan Mrdutt, MD MS
Assistant Professor of Surgery
Division of Breast and Melanoma Surgical Oncology
Mayo Clinic

Francys C. Verdial, MD, MPH
Assistant Professor of Surgery
Division of Surgical Oncology and
Gastrointestinal Surgery
Department of Surgery
Massachusetts General Hospital

Jennifer Zhang, MD
Assistant Professor of Surgery
Division of Endocrine and Oncologic Surgery
Department of Surgery
Hospital of the University of Pennsylvania

2021–2022

Linda M. Pak, MD
Assistant Professor
Department of Surgery
NYU Grossman School of Medicine

Emily N. Palmquist, MD
Assistant Professor, Department of Surgery
Breast Surgical Oncology
University of Washington School of Medicine

Marissa K. Srou-Boyle, MD
Assistant Professor, Department of Surgery
Cedars-Sinai Medical Center

Austin D. Williams, MD, MSEd
Assistant Professor
Department of Surgical Oncology
Fox Chase Cancer Center

2022–2023

Anna C. Beck, MD
Assistant Professor, Department of Surgery
Division of Surgical Oncology
University of Wisconsin
School of Medicine and Public Health

Brian Diskin, MD
Hepatopancreatobiliary Surgery Fellow
Department of Surgery
NYU Langone Health

Danielle R. Heller, MD, MHS
Breast Surgical Oncologist
Hartford Healthcare Cancer Institute
Assistant Professor, Department of Surgery
Netter School of Medicine
Quinnipiac University

V. Morgan Jones, MD
Assistant Professor of Surgery, Division of Surgical
Oncology, Department of Surgery
University of Kentucky
Markey Cancer Center

Sara Myers, MD
Breast Surgery
Brigham and Women's Hospital/Dana Farber Cancer
Institute

2023–2024

Julia Chandler, MD, MS
Assistant Professor of Surgery
Department of Surgery
University of California at San Francisco

Regina Matar-Ujvary, MD
Breast Surgery
Cleveland Clinic

Kate Pawloski, MD
Assistant Attending Surgeon
Breast Surgery, Department of Surgery
Memorial Sloan Kettering Cancer Center

Lauren Perry, MD
Clinical Assistant Professor
Michigan Medicine
University of Michigan

Rachel Sargent, MD
Clinical Assistant Professor
Department of Surgery
NYU Grossman School of Medicine



“ I wanted a program with a strong didactic program where I would be encouraged to not just learn about breast surgery, but to think critically about the literature and how to best put it into practice. Also my co-fellows—I’m so grateful to have them as friends and colleagues, now and for the rest of our careers! ”

– Julia Chandler, Breast Fellow, 2023-2024

“ Something that is unique to MSK’s program is that it illuminates the nuances, strengths, and limitations of the breast cancer literature. I feel confident in my ability to think critically about each case in clinical practice, and when there is something I don’t know, I have the tools to review the literature and formulate the best treatment plan for my patients. ”

– Danielle R. Heller, MD MHS
Breast Surgical Oncologist, Hartford Healthcare Cancer Institute
Assistant Professor, Netter School of Medicine
Quinnipiac University
Breast Fellow, 2022-2023

“ My experience at MSK helped me to feel confident beginning my first attending role due to the wide variety of clinical cases, the high surgical volume, and intensive academic preparation. While the transition to attending surgeon is a challenging one in any instance, my training at MSK gave me a solid foundation of key skills and understanding that allows me to take great care of my patients and contribute to my trainees’ education. ”

– Sarah Shubeck, Assistant Professor of Surgery,
University of Chicago, Breast Fellow, 2021-2022

“ I chose MSK because of its excellent reputation with comprehensive breast cancer care. The surgical training and medical knowledge that I learned during fellowship was unparalleled and prepared me to be a confident breast surgical oncologist as a junior attending. The compassion the surgeons at MSK have for their patients is what I valued the most and carry on in my own practice. ”

– Marissa (Srour) Boyle, Assistant Professor of Surgery,
Cedars-Sinai Medical Center, Breast Fellow, 2021-2022

“ I chose MSK because I wanted high-volume, academically challenging, and excellent fellowship training. My training at MSK helped prepare me to be a thoughtful, collaborative surgeon with not only a strong foundation in the current state of breast cancer care but also how to incorporate new data and grow and evolve as a clinician over my career. ”

– Nicole Christian, Assistant Professor
University of Colorado
Breast Fellow, 2019-2020

“ I chose fellowship at MSK for the opportunity of high operative volume, to learn from leaders in the field, and to take advantage of strong research infrastructure. ”

– Lauren Perry, Breast Fellow, 2023-2024



Memorial Sloan Kettering
Cancer Center

**Breast Service
Fellowship Program**
300 East 66th Street
New York, NY 10065
www.mskcc.org

**Department of Surgery
Education Program**
T 212-639-7537
F 212-717-3169
surfellowships@mskcc.org